<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136500</url>
  </required_header>
  <id_info>
    <org_study_id>20101021</org_study_id>
    <nct_id>NCT00136500</nct_id>
  </id_info>
  <brief_title>Clinical Research in ALS Study</brief_title>
  <acronym>CRiALS</acronym>
  <official_title>Clinical Research in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALS Recovery Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CRiALS is an umbrella protocol through which people are recruited to participate in a range&#xD;
      of research studies being conducted by the ALS Research Collaboration (ARC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research goals include elucidation of the complex relationship between ALS and related&#xD;
      neurodegenerative disorders, development of both wet and dry biomarkers of disease, and&#xD;
      delineation of the full course of the natural history of disease from the early&#xD;
      pre-symptomatic stages through established and even late-stage disease. These goals are&#xD;
      accomplished through the recruitment and evaluation of patients with ALS and related&#xD;
      diseases, family members (including people at genetic risk for ALS, but who are not yet&#xD;
      affected), and healthy controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment</measure>
    <time_frame>Annually</time_frame>
    <description>Since this is an umbrella/gateway protocol through which individuals are recruited to participate in a range of studies, outcome is assessed in terms of recruitment.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Individuals affected with ALS</arm_group_label>
    <description>This population be sporadic or familial ALS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unaffected individuals from families in which the genetic cause of ALS is known</arm_group_label>
    <description>This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Individuals affected with an ALS-related neurodegenerative disease</arm_group_label>
    <description>This would include FTD, MSP, IBMPFD, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA, blood, urine, CSF, skin biopsies&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The CRiALS research program aims to recruit three types of participants:&#xD;
&#xD;
          -  Individuals affected with ALS or a related neurodegenerative disease&#xD;
&#xD;
          -  Unaffected individuals from pedigrees in which the genetic cause of ALS is known&#xD;
&#xD;
          -  Healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age.&#xD;
&#xD;
          2. Member of at least one of the following categories:&#xD;
&#xD;
               1. Individuals affected with ALS or a related neurodegenerative disease (sporadic or&#xD;
                  familial)&#xD;
&#xD;
               2. Unaffected individuals from fALS pedigrees, including pre-symptomatic individuals&#xD;
                  at genetic risk for ALS or individuals from pedigrees of ALS related diseases.&#xD;
&#xD;
               3. Healthy controls&#xD;
&#xD;
          3. Able and willing to comply with relevant procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Subject has a condition or is in a situation which, in the PI's opinion, could confound&#xD;
        the study finding or may interfere significantly with the individual's participation and&#xD;
        compliance with the study protocol -- including but not limited to neurological,&#xD;
        psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Benatar, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Laure Grignon, MD</last_name>
    <phone>888-413-9315</phone>
    <email>fals@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Grignon, MD</last_name>
      <phone>888-413-9315</phone>
      <email>fals@med.miami.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://als-research.org/</url>
    <description>ALS Research Collaboration</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Michael Benatar</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>genetics</keyword>
  <keyword>biomarkers</keyword>
  <keyword>pre-symptomatic</keyword>
  <keyword>natural history</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

